Clinical evaluation of omega-3 fatty acids in psoriasis

Adil, Mohammad; Singh, P. K.; Maheshwari, Kopal

doi:10.5114/dr.2017.68778

Cited by 10 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After a drop out of 5 patients in group A and 7 patients in group B, 95 patients and 93 patients completed the study from the two groups respectively ( Table 1). These findings have already been published in a paper by our group [13].…”

Section: Resultssupporting

confidence: 73%

Omega-3 fatty acids and quality of life in psoriasis: an open, randomised controlled study

Adil¹

2019

Our Dermatol Online

Self Cite

View full text Add to dashboard Cite

Background: Omega-3 fatty acids have been reported to reduce disease severity in psoriasis in various studies. This study aims to study the effects of omega-3 fatty acid supplementation on the quality of life in psoriasis.Methods: This open, non blinded interventional study divided patients of psoriasis with affected body surface area of less than <10% into two groups of 100 patients each. Group A was given topical paraffin with 1.8 grams of omega-3 fatty acids daily in three divided doses. Group B was advised topical paraffin application once a day. Oral antihistaminics were added as per need. Baseline patient characteristics like age, sex and severity of psoriasis by Psoriasis Area Severity Index and Dermatology Life Quality Index was assessed. The patients were followed up for 12 weeks and change in DLQI was noticed.Results: Baseline DLQI in group A changed by 2.96 points from 11.47 ± 3.90 to 8.51 ± 3.36. (p <0.00001) and by 1.27 points from 11.69 ± 3.75 to 10.42 ± 3.61 in group B (p<0.00001). The change in the DLQI between the two groups was statistically significant (p=0.0002).Conclusion: Omega-3 fatty acids appear to produce a statistically significant improvement in the quality of life in psoriasis patients.

show abstract

Section: Resultssupporting

confidence: 73%

Omega-3 fatty acids and quality of life in psoriasis: an open, randomised controlled study

Adil¹

2019

Our Dermatol Online

Self Cite

View full text Add to dashboard Cite

show abstract

“…The application of several scales of disease advancement is extremely important in order to properly assess the therapy efficacy. It must be taken into account that PASI, ‘a golden standard’ constitutes an interpretative challenge due to the fact that there is no linear correlation between PASI value and disease exacerbation, with no account given to patients’ subjective complaints . With regards to BSA, it should be noted that it cannot be treated as an independent index for disease advancement, since it does not take into consideration the morphology of observed changes and may be erroneously overstated …”

Section: Discussionmentioning

confidence: 99%

Clinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgaris

et al. 2018

View full text Add to dashboard Cite

Background Psoriasis course involves increased secretion of pro‐inflammatory cytokines, among others, a beta transforming growth factor (TGFβs) and its receptors. Cyclosporine A (CsA), an immunosuppressive medicine with the molecular mechanism of operation connected with the properties of cell cycle suppression, is often used in the treatment of severe forms of psoriasis. The efficacy of therapy is assessed based on the disease clinical progression indexes – Psoriasis Area and Severity Index (PASI), body surface area (BSA), and Dermatology Life Quality Index (DLQI). The aim of the study was the evaluation of the efficacy of the CsA treatment of patients with psoriasis vulgaris, based on the clinical parameters and an assessment of the expression profiles of TGFβs and TGFβRs, depending on the concurrent diabetes and metabolic syndrome. Methods The group under study composed of 32 patients (15 with the metabolic syndrome, seven with diabetes) treated with CsA for 84 days. The molecular analysis included extraction of RNA, assessment of TGβF1‐3, TGFβRI‐III gene expression with the use of the RTqPCR method. The clinical assessment of the effects of this pharmacotherapy involved evaluation of the parameters: PASI, BSA, DLQI before therapy commencement, on the 42nd and 84th days of therapy. Results A statistically significant change in the transcription activity of TGFβ1 in patients with and without diabetes (P = 0.018) and patients with and without metabolic syndrome (P = 0.023) was shown that on the 84th day of therapy. Conclusions TGFb1 may be claimed as the supplementary molecular marker to evaluate the efficacy of CsA therapy. It seems that systemic diseases have an effect on the efficacy of the applied pharmacotherapy and the course of psoriasis.

show abstract

“…However, after 3 months of treatment, there was not significant differences in PASI decrease in the fish oil group, similarly to the result verified by Soyland, et al [25], where sixty-two plaque psoriasis patients received 6 gr of fish n-3 fatty acids for 4 months. Nevertheless, several studies presented an improvement of the PASI after oral treatment [13] and fish oil infusion [12,26].…”

Section: Discussionmentioning

confidence: 99%

“…The beneficial effects after supplementation with n-3 polyunsaturated fatty acids in psoriasis are still controversial. Some studies have reported improvement in erythema, scaling, infiltration, itching, and area of skin involved [10][11][12][13] as well as reduction in inflammatory markers [10,12], whereas others have not found significant reduction in these parameters [14,15].…”

Section: Introductionmentioning

confidence: 99%

Supplementation with fish oil improves life quality, and decreases inflammatory status and oxidative stress in psoriasis

Mari¹,

Santos²,

Alfieri³

et al. 2018

Clin Res Trial

View full text Add to dashboard Cite

This study verified the effects of fish oil n-3 fatty acids on the inflammatory profile, redox state, adhesion molecules and impact on the life quality of patients with psoriasis. Forty patients with chronic plaque psoriasis were randomized to one of two groups: fish oil group (n=20), which received 3g/d of fish oil n-3 fatty acids (10 capsules) and control group (n=20), which maintained their usual diet. Inflammatory biomarkers, nitro-oxidative stress including lipid hydroperoxides (LOOH) in plasma and red blood cells, advanced oxidation protein products (AOPP), nitric oxide metabolites (NOx), sulfhydryl groups and total radical-trapping antioxidant parameter (TRAP) were measured as well as adhesion molecules and plasminogen activator inhibitor type-1; Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) were also evaluated. All parameters were measured at baseline and after 90 days of supplementation. The group receiving fish oil showed decreased erythrocyte sedimentation rate (ESR) (p=0,007), LOOH in red blood cells (p=0,048), AOPP (p=<0,001) and increased sulfhydryl groups (p=0,001), TRAP (p=0,010) and DLQI. There were not significant results in PASI, adhesion molecules, PAI-1, NOx, and plasma LOOH. Inter-group changes (p<0.05) verified an improvement in the patient's life quality measured by DLQI, a decrease in AOPP and an increase in SH. The present study indicated that ingestion of capsules of n-3 fish oil fatty acids was able to improve life quality, to reduce inflammatory status, to decrease lipid peroxidation and protein oxidation, and to increase the total antioxidant capacity in patients with psoriasis.

show abstract

Clinical evaluation of omega-3 fatty acids in psoriasis

Cited by 10 publications

References 21 publications

Omega-3 fatty acids and quality of life in psoriasis: an open, randomised controlled study

Omega-3 fatty acids and quality of life in psoriasis: an open, randomised controlled study

Clinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgaris

Supplementation with fish oil improves life quality, and decreases inflammatory status and oxidative stress in psoriasis

Contact Info

Product

Resources

About